Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · IEX Real-Time Price · USD
6.68
+0.02 (0.30%)
At close: Jul 2, 2024, 4:00 PM
6.60
-0.08 (-1.20%)
After-hours: Jul 2, 2024, 7:42 PM EDT
Ocular Therapeutix Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Ocular Therapeutix stock have an average target of 15.83, with a low estimate of 11 and a high estimate of 22. The average target predicts an increase of 136.98% from the current stock price of 6.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for OCUL stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Hold → Strong Buy Upgrades $7 → $11 | Hold → Strong Buy | Upgrades | $7 → $11 | +64.67% | Jun 20, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $15 | Buy | Maintains | $15 | +124.55% | Jun 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +109.58% | Jun 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 → $14 | Strong Buy | Maintains | $16 → $14 | +109.58% | May 8, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $24 → $22 | Buy | Maintains | $24 → $22 | +229.34% | May 8, 2024 |
Financial Forecast
Revenue This Year
67.52M
from 58.44M
Increased by 15.53%
Revenue Next Year
79.32M
from 67.52M
Increased by 17.48%
EPS This Year
-1.20
from -1.02
EPS Next Year
-1.07
from -1.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 75.2M | 92.4M | 152.7M | 321.7M | 426.2M |
| Avg | 67.5M | 79.3M | 100.9M | 184.6M | 329.4M |
| Low | 59.2M | 68.6M | 72.9M | 106.7M | 223.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 28.7% | 36.9% | 92.5% | 218.7% | 130.9% |
| Avg | 15.5% | 17.5% | 27.2% | 82.9% | 78.5% |
| Low | 1.3% | 1.6% | -8.1% | 5.8% | 20.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.87 | -0.58 | -0.74 |
| Avg | -1.20 | -1.07 | -1.21 |
| Low | -1.34 | -1.27 | -1.57 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.